Single-use bioprocessing market seen reaching $107.83 billion by 2035

Market Research Future projects the global single-use bioprocessing market will grow from $35.35 billion in 2026 to $107.83 billion by 2035, driven by biologics pipeline expansion, regulatory harmonization and CDMO capacity growth. The report points to faster adoption of disposable systems across commercial manufacturing, especially in North America and Asia-Pacific.

Why it matters: - The market is moving from a niche clinical tool to a core biomanufacturing platform as biologics output expands. - Single-use systems cut facility build times and reduce the validation burden tied to stainless-steel infrastructure. - The shift affects biopharma companies, CDMOs and academic manufacturers that need faster changeovers and lower contamination risk.

What happened: - Market Research Future estimates the global single-use bioprocessing market will rise from USD 35.35 billion in 2026 to USD 107.83 billion by 2035. - The forecast implies a 13.2% CAGR during 2026–2035. - The market base was estimated at USD 31.23 billion in 2025. - The report ties growth to biologics pipeline expansion, regulatory harmonization and CDMO capacity expansion. - The research notes a free sample and full report are available through the company’s sample request page and the detailed market report.

The details: - The global biologics pipeline surpassed 8,500 active candidates in 2025. - Monoclonal antibodies, bispecific antibodies and antibody-drug conjugates made up more than 55% of late-stage clinical programs. - Single-use systems remove the 18-to-24-month lead time tied to stainless-steel facility construction. - FDA Process Validation Guidance updated in 2025 recognized closed single-use systems as meeting sterility assurance requirements without traditional autoclave validation. - The report says that reduced the compliance documentation burden by an estimated 30% for new facility filings. - The European Medicines Agency’s revised Annex 1, enforced from August 2024, pushed adoption by requiring contamination-control strategies. - Single-use bioreactors held about 42% of product revenue in 2025. - Sensors and analytics were the fastest-growing product segment at 17.5% CAGR for 2026–2035. - Filtration assemblies reached USD 5.8 billion in 2025. - Bags, tubing and connectors held about 18% market share in 2025. - Mixing systems are projected to grow at 13.8% CAGR through 2035. - Upstream processing led workflows with about 57% revenue share in 2025. - Downstream processing is forecast to grow fastest at 14.6% CAGR. - Biopharmaceutical companies were the largest end-user group with about 69.5% revenue share in 2025. - CDMOs are the fastest-growing end-user segment at 16.0% CAGR. - Commercial-scale manufacturing represented about 72% of revenue in 2025. - Clinical-scale demand is projected to grow at 14.5% CAGR.

Between the lines: - The forecast suggests disposable systems are benefiting from structural manufacturing demand, not short-cycle healthcare spending. - Regulatory clarity is lowering adoption barriers and making single-use validation easier across regions. - CDMO growth points to more outsourcing by smaller biotechs that want flexible, multi-product capacity without cross-contamination risk. - Asia-Pacific’s rapid biologics buildout and North America’s regulatory depth are shaping where the next wave of demand concentrates. - The competitive field remains concentrated, but AI-enabled process analytics could widen the gap for early movers.

What's next: - North America remains the largest regional market at about 38.2% share in 2025, led by the United States. - Asia-Pacific is the fastest-growing region, with a projected 14.2% CAGR from 2026 to 2035. - Europe’s market is expected to keep expanding as EU harmonization narrows country-level differences. - By 2030, the report expects about 40% of newly approved biologics to use single-use process analytical technology for real-time quality assurance. - The report also says start-ups have raised more than USD 800 million in venture funding for bioprocessing decision-support tools since 2023.

The bottom line: - Single-use bioprocessing is on track to become the default manufacturing architecture for a growing share of biologics production, with regulation, outsourcing and digital monitoring all accelerating adoption.